Department of Pathology, University of New Mexico, Albuquerque, New Mexico.
Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
Int J Lab Hematol. 2020 Aug;42(4):418-422. doi: 10.1111/ijlh.13212. Epub 2020 Apr 16.
Enumeration of blasts and promonocytes is essential for World Health Organization (WHO) classification of myelomonocytic neoplasms. The accuracy of distinguishing blasts, promonocytes and monocytes, including normal vs abnormal monocytes, remains controversial. The objective of this analysis is to assess concordances between experienced hematopathologists in classifying cells as blasts, promonocytes, and monocytes according to WHO criteria. Each of 11 hematopathologists assessed glass slides from 20 patients [12 with chronic myelomonocytic leukemia (CMML) and 8 with acute myeloid leukemia (AML)] including blood and BM aspirate smears, and limited nonspecific esterase (NSE) stains. All cases were blindly reviewed. Fleiss' extension of Cohen's kappa for multiple raters was used on these variables, separately for peripheral blood (PB) and bone marrow (BM). Spearman's rank correlation was used to assess correlations between each pair of hematopathologists for each measurement. For the classification based on the sum of blasts and promonocytes in the BM, Fleiss' kappa was estimated as 0.744. For PB, categorizing patients according to the sum of blasts and promonocytes, Fleiss' kappa was estimated as 0.949. Distinction of abnormal monocytes from normal monocytes in PB did not achieve a good concordance and showed strong evidence of differences between hematopathologists (P < .0001). The hematopathologists achieved a good concordance rate of 74% in CMML vs AML classification and a high k rate, confirming that criteria for defining the blasts equivalents (blasts plus promonocytes) could be applied consistently. Identification of monocyte subtypes (abnormal vs normal) was not concordant. Our results support the practice of combining blasts/promonocytes into a single category.
对 blast 和原始单核细胞进行计数对于世界卫生组织(WHO)髓系肿瘤的分类至关重要。区分 blast、原始单核细胞和单核细胞(包括正常单核细胞与异常单核细胞)的准确性仍存在争议。本分析旨在评估 11 位血液病理学家根据 WHO 标准对细胞进行分类的一致性,包括 blast、原始单核细胞和单核细胞。每位血液病理学家评估了 20 位患者(包括 12 位慢性髓系单核细胞白血病(CMML)患者和 8 位急性髓系白血病(AML)患者)的玻片,包括血液和 BM 抽吸涂片,以及有限的非特异性酯酶(NSE)染色。所有病例均进行了盲法评估。对这些变量分别进行了外周血(PB)和骨髓(BM)的 Fleiss 扩展 Cohen's kappa 多评估。使用 Spearman 秩相关来评估每位血液病理学家对每种测量结果的相关性。对于基于 BM 中 blast 和原始单核细胞总和的分类,Fleiss' kappa 估计值为 0.744。对于 PB,根据 blast 和原始单核细胞总和对患者进行分类,Fleiss' kappa 估计值为 0.949。在 PB 中区分异常单核细胞与正常单核细胞未达到良好的一致性,并且表明血液病理学家之间存在明显差异(P<.0001)。血液病理学家在 CMML 与 AML 分类中达到了 74%的良好一致性率和较高的 k 值,这证实了可以一致地应用定义 blast 等效物(blast 加原始单核细胞)的标准。单核细胞亚型(异常与正常)的识别不一致。我们的结果支持将 blast/原始单核细胞合并为一个单一类别。